Domizi R, Adrario E, Damiani E, et al. - By performing this single-centre, randomized, double-blind, placebo-controlled phase II trial, researchers investigated if improved microvascular perfusion during sepsis may result from the infusion of IgM (immunoglobulins M)-enriched immunoglobulins. Participants were adult patients with a diagnosis of sepsis or septic shock for less than 24 h. An intravenous infusion of 250 mg/kg (5 mL/kg) per day of IgM-enriched immunoglobulins (Pentaglobin, n = 10) for 72 h or placebo (NaCl 0.9%, n = 9) was administered to patients. By means of Incident Dark Field videomicroscopy, the evaluation of sublingual microcirculation was done at baseline and after 24 and 72 h of infusion. In the Pentaglobin group, they noted a rise in the perfused vessel density for small vessels (diameter < 20 micron), whereas a reduction was noted in the placebo group. In the Pentaglobin group, a rise in the microvascular flow index for small vessels was observed at 24 h, and this was found to be reduced at 72 h in the placebo group. According to findings, an increase in sublingual microvascular perfusion may be seen in relation to a 72-h infusion of IgM-enriched immunoglobulins (Pentaglobin) in patients with sepsis or septic shock.